Pancreatic ribonuclease (RNase A)

Pancreatic ribonuclease (RNase A) is a highly studied, small mammalian enzyme that catalyzes the endonucleolytic cleavage of RNA at the 3’,5’-phosphodiester bonds following pyrimidine residues, producing smaller RNA fragments[7][3][2]. It is a secreted protein, primarily produced in the pancreas, with a central role in the digestion of dietary RNA[7][8]. RNase A’s catalytic triad, composed of His12, His119, and Lys41, enables precise substrate recognition and efficient catalysis[1][9]. While related RNase enzymes (such as angiogenin) have recognized roles in pathophysiology and are explored as therapeutic agents or biomarkers, pancreatic RNase A itself is not directly implicated as a therapeutic target nor linked causally to major diseases[8][7]. It has, however, utility in molecular biology for removal of RNA in DNA preparation and analytical workflows[2]. RNase A is a model system in protein folding and enzymology, with a well-characterized tertiary structure featuring four disulfide bonds and a kidney-shaped fold[1][9]. Caveats and limitations: - RNase A is a classic biochemical workhorse and a model enzyme, not an established therapeutic target or drug target[7][8]; other members of the RNase A superfamily (such as angiogenin/RNase 5) may have biological or therapeutic significance in cancer and other diseases, which should not be conflated with pancreatic RNase A. - There are no widely used clinical drugs that specifically target pancreatic RNase A. - Pancreatic ribonuclease is sometimes used experimentally as a reagent but is not an endogenous receptor/drug target in the typical pharmacological sense. If you require information on a disease-associated ribonuclease, such as angiogenin or eosinophil-derived neurotoxin, please specify.

Other names

Ribonuclease 1RNase 1Bovine pancreatic ribonucleaseRibonuclease A

Hydrolysis of RNA, Cleavage of 3’,5’-phosphodiester bonds in RNA (after pyrimidine nucleotides)